Search research articles
Contact Us
Filters
Showing results (101-110 of 109) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 109 results.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology
|
March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and Anxiety
Kenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Neurology (E-Cronicon)
|
December 29, 2025
Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS)
Kenneth Blum, Eric R Braverman, Milan Makale, et al.
Journal of Addiction Psychiatry
|
September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and Present
Kenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Research Square
|
December 3, 2025
Computational GWAS Meta Meta Analysis Revealing Cross Talk Between Cannabis CNR1 and DRD2 Receptors Optimizing Long-Term Outcomes for Cannabis Use Disorder (CUD) By Enhancing Dopamine Homeostasis Promoting High-Quality Cannabis Medicinals
Kenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Journal of Addiction Psychiatry
|
December 5, 2024
Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy
Foojan Zeine, Nicole Jafari, David Baron, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 109) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 109 results.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
British Journal of Healthcare and Medical Research
|
May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?
Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology
|
March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and Anxiety
Kenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Neurology (E-Cronicon)
|
December 29, 2025
Neurospirituality Connectome - Role in Neurology and Reward Deficiency Syndrome (RDS)
Kenneth Blum, Eric R Braverman, Milan Makale, et al.
Journal of Addiction Psychiatry
|
September 11, 2025
Precision Genomics: A Reality Having Universal Impact in a New Era of Psychiatry - Lessons Learned, Past and Present
Kenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Research Square
|
December 3, 2025
Computational GWAS Meta Meta Analysis Revealing Cross Talk Between Cannabis CNR1 and DRD2 Receptors Optimizing Long-Term Outcomes for Cannabis Use Disorder (CUD) By Enhancing Dopamine Homeostasis Promoting High-Quality Cannabis Medicinals
Kenneth Blum, Alireza Sharafshah, Jag Khalsa, et al.
Journal of Addiction Psychiatry
|
December 5, 2024
Solving the Global Opioid Crisis: Incorporating Genetic Addiction Risk Assessment with Personalized Dopaminergic Homeostatic Therapy and Awareness Integration Therapy
Foojan Zeine, Nicole Jafari, David Baron, et al.
Page
of 11